Objectives. Thymidine kinase (TK) has an important role in DNA synthesis and is thus related to cell proliferation and turnover. Traditionally, TK has been measured by enzymatic activity or radioimmunoassays. These assays are difficult to adapt to random access instruments. The aim of this study was to evaluate a new immunological sandwich assay for detection of TK peptides in serum from breast cancer patients. Material and methods. Serum samples were collected from patients with breast cancer and stored frozen at -70°C. The samples were collected after surgery, after metastatic tumor recurrence and after chemotherapy due to tumour recurrence. Patients' serum samples were analysed by the TK enzyme-linked immunosorbent assay (ELISA). Results. In receiver operating characteristics (ROC) analyses of TK1 for diagnosis of breast cancer, the area under the curve (AUC) for samples collected four weeks after surgery was 0.56 (95% CI 0.47-0.65), for samples collected postsurgically after tumour recurrence 0.73 (95% CI 0.65-0.80), and after chemotherapy 0.64 (95% CI 0.56-0.72). Conclusions. This study indicates that the tumour proliferation marker TK has a potential as a serum marker in breast cancer. Further studies are warranted to verify this observation.
CITATION STYLE
Carlsson, L., Larsson, A., & Lindman, H. (2009). Elevated levels of Thymidine kinase 1 peptide in serum from patients with breast cancer. Upsala Journal of Medical Sciences, 114(2), 116–120. https://doi.org/10.1080/03009730802688835
Mendeley helps you to discover research relevant for your work.